secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biofrontera Inc. (BFRI)
CIK:        0001858685
Form:       8-K
Filed at:   2025-03-21T23:59:59+00:00
Accession:  0001493152-25-011083
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M
--------------------------------------------------------------------------------

- Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.
- Q4 2024 net loss $1.4M ($0.19/share) vs net income $3.5M ($1.65/share) in Q4 2023 due to prior-year legal settlement gain.
- Cash and equivalents $5.9M at Dec 31, 2024 vs $1.3M at Dec 31, 2023; Ameluz transfer price reduced from 50% to 25% through 2025.
- Placed 100 RhodoLED XL lamps since June 2024 launch; FDA approved up to 3 tubes of Ameluz per treatment.
- Phase 3 Study for Ameluz-PDT in superficial BCC achieved statistically significant results; initiated Phase 1 PK study for AK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/0001493152-25-011083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858685/000149315225011083/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-011083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer